Clinical Research Trials

Our extensive experience in clinical research trials, combined with our relationships with leading universities and pharmaceutical companies, supports the advancement of early detection, the slowing of disease progress and our quest to end Alzheimer’s disease.

Research partners include Harvard University, Johns Hopkins University, University of Southern California, Eli Lilly, Eisai, Biogen and many others.

The clinical research trials we use employ the latest methodologies and are based on the most encouraging theories. By joining other participants, you are helping develop medical treatments as well as breakthrough technologies.

We cover participants’ clinical trial costs, offer access to our other memory programs and, in some cases, compensation may be available for time and travel.

If you are interested in participating or learning more about our clinical research trials, please call 305.514.8710 or email clinicaltrials@miamijewishhealth.org  or RCastaneda@miamijewishhealth.org

 


 

CURRENT CLINICAL TRIALS

Pharmaceutical study for people living in the community who are either starting to note some concerning changes in their memory or those who have been recently diagnosed with Early Stage or Mild Alzheimer’s Disease.

  • Name of Study: EISAI BAN 2401 – G000-301
  • Description of Study: This is a Phase III placebo-controlled, double-blind study, evaluating the safety, tolerability and efficacy of BAN2401 in subjects with Early Alzheimer’s Disease.
  • Indication: Meets criteria for probable Mild Cognitive Impairment (MCI) – Mild Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 90 years
  • Duration of Study: 18 months (optional open-label extension)

 

Academic study for people living in the community who are starting to note some concerning changes in their memory.

  • Name of Study: MIND Study – Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia Study, funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California
  • Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) Phase II study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI.
  • Indication: Mild Cognitive Impairment or Memory Loss
  • Recruiting Participant Age: 55 years +
  • Duration of Study: 2 years

 

Academic study for people who reside in either a nursing home or assisted living facility and have been diagnosed with Alzheimer’s Disease and are currently experiencing symptoms of severe agitation.

  • Name of Study: Dronabinol – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, double-blind randomized clinical trial of Dronabinol in Nursing Home patients with severe agitation – AD.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age:  60 – 90 years
  • Duration of Study: 3 weeks

 

Academic study for people living in the community who have been diagnosed with Alzheimer’s Disease and are currently experiencing symptoms of moderate to severe agitation.

  • Name of Study: S-CitAD – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, masked study, assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age:  18 years +
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

 

Pharmaceutical study for people living in the community who have been diagnosed with Mild to Moderate Alzheimer’s Disease or those who are currently experiencing certain memory problems that can be diagnosed clinically as Mild to Moderate Alzheimer’s Disease.

  • Name of Study: T3D Therapeutics – T3D959
  • Description of Study: This is a Phase II placebo-controlled, double–blind randomized study, assessing the safety and efficacy of T3D-959 in subjects with Mild to Moderate Alzheimer’s Disease.
  • Indication: Mild to Moderate Alzheimer’s Disease
  • Recruiting Participant Age:  50 – 90 years
  • Duration of Study: Approximately 24 weeks

 

Pharmaceutical study for people living in the community who are either starting to note some concerning changes in their memory or those who have been recently diagnosed with Early Stage or Mild Alzheimer’s Disease.

  • Name of Study: Agene Bio – AGB101 MCD
  • Description of Study: This is a Phase III placebo-controlled, double-blind study, evaluating the efficacy and safety of AGB101 (low-dose levetiracetam) in subjects with Early Alzheimer’s Disease.
  • Indication: Meets criteria for Mild Cognitive Impairment (MCI) – Mild Alzheimer’s Disease
  • Recruiting Participant Age:  55 – 85 years
  • Duration of Study: 18 months

 

Pharmaceutical study for people living in the community who have been diagnosed with Alzheimer’s Disease and are currently experiencing symptoms of moderate to severe agitation.

  • Name of Study: Avanir – 17 AVP-786-305
  • Description of Study: This is a Phase III placebo controlled, double-blind clinical trial, testing the efficacy, safety and tolerability of AVP-786 for treating symptoms of agitation associated with dementia in patients with Dementia of Alzheimer’s type.
  • Indication: Probable Alzheimer’s disease with Moderate-Severe Agitation
  • Recruiting Participant Age: 50 – 90 years
  • Duration of Study: Approximately 4 months (optional open-label extension)

 

Pharmaceutical study for people living in the community and previously participated in a study where Aducanumab was administered.

  • Name of Study: Biogen – 221AD304
  • Description of Study: Phase 3B open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205.
  • Indication: Probable Alzheimer’s disease
  • Recruiting Participant Age: 50 – 85 years
  • Duration of Study: 126 weeks

Live Life Better

Contact Us Today